The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Editorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationThe Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Campbell, P. J., Scott, L. M., Buck, G., Wheatley, K., East, C. L., Marsden, J. T., Duffy, A., Boyd, E. M., Bench, A. J., Scott, M. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67785-9 · Cited by 653
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Self-citationWernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2005-12-4824 · Cited by 483
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R. M., Finazzi, G., Guerini, V., Fabris, F., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064287 · Cited by 449
Self-citationRatio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2007-08-107748 · Cited by 440
Lacout, C., Pisani, D. F., Tulliez, M., Gachelin, F. M., Vainchenker, W., & Villeval, J.-L. (2006) · Blood · doi:10.1182/blood-2006-02-002030 · Cited by 435
Bone-Marrow Responses in Polycythemia Vera
(1974) · New England Journal of Medicine · doi:10.1056/nejm197406132902419 · Cited by 420
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R., & for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) · Blood · doi:10.1182/blood-2006-08-042515 · Cited by 416
Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., Tsuboi, K., Nitta, M., Miyazaki, H., Iida, S., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3471 · Cited by 373
Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Longo, G., Pancrazzi, A., Ponziani, V, Bogani, C., Ferrini, P. R., Rambaldi, A., Guerini, V, et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404854 · Cited by 368
Self-citationTheocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.-S., Lippert, E., Talmant, P., Tichelli, A., Hermouet, S., & Skoda, R. C. (2007) · Blood · doi:10.1182/blood-2006-12-062125 · Cited by 326
Carobbio, A., Finazzi, G., Guerini, V., Spinelli, O., Delaini, F., Marchioli, R., Borrelli, G., Rambaldi, A., & Barbui, T. (2007) · Blood · doi:10.1182/blood-2006-09-046342 · Cited by 320
Wolanskyj, A. P., Lasho, T. L., Schwager, S. M., McClure, R. F., Wadleigh, M., Lee, S. J., Gary Gilliland, D., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05764.x · Cited by 303
Self-citationScott, L. M., Scott, M. A., Campbell, P. J., & Green, A. R. (2006) · Blood · doi:10.1182/blood-2006-04-018259 · Cited by 294
Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., Jones, C., Zehnder, J. L., Lilleberg, S. L., & Weissman, I. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601462103 · Cited by 286
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278
Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A. M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., et al. (2007) · Blood · doi:10.1182/blood-2007-07-099184 · Cited by 258
Self-citationPassamonti, F., Rumi, E., Pietra, D., Porta, M. G. D., Boveri, E., Pascutto, C., Vanelli, L., Arcaini, L., Burcheri, S., Malcovati, L., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3826 · Cited by 253
Tefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationLippert, E., Boissinot, M., Kralovics, R., Girodon, F., Dobo, I., Praloran, V., Boiret-Dupré, N., Skoda, R. C., & Hermouet, S. (2006) · Blood · doi:10.1182/blood-2006-01-013540 · Cited by 234
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
Antonioli, E., Guglielmelli, P., Pancrazzi, A., Bogani, C., Verrucci, M., Ponziani, V, Longo, G., Bosi, A., & Vannucchi, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2403902 · Cited by 229
Self-citationV617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis
Campbell, P. J. (2006) · Blood · doi:10.1182/blood-2005-08-3395 · Cited by 224
The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera
Tefferi, A., Lasho, T. L., Schwager, S. M., Strand, J. S., Elliott, M., Mesa, R., Li, C., Wadleigh, M., Lee, S. J., & Gilliland, D. G. (2006) · Cancer · doi:10.1002/cncr.21645 · Cited by 221
Self-citationMolecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Zaleskas, V. M., Krause, D. S., Lazarides, K., Patel, N., Hu, Y., Li, S., & Van Etten, R. A. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000018 · Cited by 220
Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2404948 · Cited by 212
Self-citationTefferi, A., Lasho, T. L., Schwager, S. M., Steensma, D. P., Mesa, R. A., Li, C., Wadleigh, M., & Gary Gilliland, D. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05776.x · Cited by 207
Self-citationPolycythemia vera is not initiated by JAK2 mutation
Nussenzveig, R. H., Swierczek, S. I., Jelinek, J., Gaikwad, A., Liu, E., Verstovsek, S., Prchal, J. F., & Prchal, J. T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.11.012 · Cited by 204
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
Bumm, T. G. P., Elsea, C., Corbin, A. S., Loriaux, M., Sherbenou, D., Wood, L., Deininger, J., Silver, R. T., Druker, B. J., & Deininger, M. W. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2210 · Cited by 198
Dupont, S., Massé, A., James, C., Teyssandier, I., Lécluse, Y., Larbret, F., Ugo, V., Saulnier, P., Koscielny, S., Le Couédic, J. P., et al. (2007) · Blood · doi:10.1182/blood-2006-10-054940 · Cited by 197
Delhommeau, F., Dupont, S., Tonetti, C., Massé, A., Godin, I., Couedic, J.-P. L., Debili, N., Saulnier, P., Casadevall, N., Vainchenker, W., et al. (2007) · Blood · doi:10.1182/blood-2006-03-007146 · Cited by 178
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
Shide, K., Shimoda, H. K., Kumano, T., Karube, K., Kameda, T., Takenaka, K., Oku, S., Abe, H., Katayose, K. S., Kubuki, Y., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405043 · Cited by 175
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Antonioli, E., Guglielmelli, P., Poli, G., Bogani, C., Pancrazzi, A., Longo, G., Ponziani, V., Tozzi, L., Pieri, L., Santini, V., et al. (2007) · Haematologica · doi:10.3324/haematol.11653 · Cited by 167
Self-citationClinical correlates of JAK2V617F allele burden in essential thrombocythemia
Kittur, J., Knudson, R. A., Lasho, T. L., Finke, C. M., Gangat, N., Wolanskyj, A. P., Li, C., Wu, W., Ketterling, R. P., Pardanani, A. D., et al. (2007) · Cancer · doi:10.1002/cncr.22663 · Cited by 157
Self-citationCheung, B., Radia, D., Pantelidis, P., Yadegarfar, G., & Harrison, C. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05858.x · Cited by 156
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Pardanani, A. D., Fridley, B. L., Lasho, T. L., Gilliland, D. G., & Tefferi, A. (2007) · Blood · doi:10.1182/blood-2007-06-095703 · Cited by 153
Self-citationLarsen, T. S., Pallisgaard, N., Møller, M. B., & Hasselbalch, H. C. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00960.x · Cited by 152
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera
Ishii, T., Bruno, E., Hoffman, R., & Xu, M. (2006) · Blood · doi:10.1182/blood-2006-04-017392 · Cited by 148
Finazzi, G., Rambaldi, A., Guerini, V., et al. (2007) · Haematologica · doi:10.3324/haematol.10634 · Cited by 142
Kröger, N. M., Badbaran, A., Holler, E., Hahn, J. R., Kobbe, G., Bornhäuser, M., Reiter, A., Zabelina, T., Zander, A. R., & Fehse, B. (2006) · Blood · doi:10.1182/blood-2006-08-039909 · Cited by 141
Vainchenker, W., & Constantinescu, S. (2005) · Hematology. American Society of Hematology. Education Program · doi:10.1182/asheducation-2005.1.195 · Cited by 140
Hookham, M. B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A. C., Vainchenker, W., Percy, M. J., McMullin, M. F., Constantinescu, S. N., & Johnston, J. A. (2007) · Blood · doi:10.1182/blood-2006-08-039735 · Cited by 135
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Jones, A., Silver, R., Waghorn, K., Curtis, C., Kreil, S., Zoi, K., Hochhaus, A., Oscier, D., Metzgeroth, G., Lengfelder, E., et al. (2005) · Blood · doi:10.1182/blood-2005-09-3917 · Cited by 132
Guglielmelli, P., Zini, R., Bogani, C., Salati, S., Pancrazzi, A., Bianchi, E., Mannelli, F., Ferrari, S., Bousse‐Kerdilès, M. L., Bosi, A., et al. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0351 · Cited by 127
Self-citationTefferi, A., Lasho, T. L., Mesa, R. A., Pardanani, A. D., Ketterling, R. P., & Hanson, C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404711 · Cited by 124
Self-citationTaksin, A., Couedic, J. P. L., Dusanter‐Fourt, I., Massé, A., Giraudier, S., Katz, A., Wendling, F., Vainchenker, W., Casadevall, N., & Debili, N. (1999) · Blood · doi:10.1182/blood.v93.1.125 · Cited by 102
Williams, D. M., Kim, A. H., Rogers, O. C., Spivak, J. L., & Moliterno, A. R. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.010 · Cited by 100
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility
Steensma, D. P. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060007 · Cited by 78
Oncogenic mechanisms in myeloproliferative disorders
Delhommeau, F., Pisani, D. F., James, C., Casadevall, N., Constantinescu, S. N., & Vainchenker, W. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6272-7 · Cited by 78
Gale, R., Allen, A., Nash, M., & Linch, D. (2007) · Blood · doi:10.1182/blood-2006-06-029769 · Cited by 77
Vannucchi, A. M., Pancrazzi, A., Bogani, C., Antonioli, E., & Guglielmelli, P. (2006) · Leukemia · doi:10.1038/sj.leu.2404209 · Cited by 76
Self-citationPardanani, A. D., Lasho, T. L., Finke, C. M., Mesa, R. A., Hogan, W. J., Ketterling, R. P., Gilliland, D. G., & Tefferi, A. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0175 · Cited by 72
Self-citationLasho, T. L., Mesa, R. A., Gilliland, D. G., & Tefferi, A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05682.x · Cited by 60
Self-citationHeller, P. G., Lev, P. R., Salim, J. P., Kornblihtt, L. I., Goette, N. P., Chazarreta, C. D., Glembotsky, A. C., Vassallu, P. S., Marta, R. F., & Molinas, F. C. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00688.x · Cited by 60
The Genetic Basis of Myeloproliferative Disorders
Skoda, R. C. (2007) · Hematology · doi:10.1182/asheducation-2007.1.1 · Cited by 55
Pemmaraju, N., Moliterno, A. R., Williams, D. M., Rogers, O. C., & Spivak, J. L. (2007) · Leukemia · doi:10.1038/sj.leu.2404755 · Cited by 51
Gaikwad, A. S., Nussenzveig, R. H., Liu, E., Gotschalk, S., Chang, K., & Prchal, J. T. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.12.007 · Cited by 38
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis
Bogani, C., Guglielmelli, P., Antonioli, E., Pancrazzi, A., Bosi, A., & Vannucchi, A. M. (2007) · Haematologica · doi:10.3324/haematol.10527 · Cited by 30
Self-citationDiagnosis of the myeloproliferative disorders: Resolving phenotypic mimicry
Spivak, J. L. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70051-1 · Cited by 21
Rudzki, Z., Sacha, T., Stój, A., Czekalska, S., Wójcik, M., Skotnicki, A. B., Grabowska, B., Zdunczyk, A., Okoń, K., & Stachura, J. (2007) · International Journal of Hematology · doi:10.1532/ijh97.e0607 · Cited by 17
Cited by
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citationTefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationTefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
Self-citation
Metadata
- Authors
- Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A.
- Venue
- Leukemia
- Published
- 2008-05-22
- Volume
- 22
- Issue
- 7
- Pages
- 1299-1307
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1982105192
- Cited by
- 294
- References
- 69
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.